As GH response in the first year is the most important predictive factor of overall treatment success, the study is presumed to provide clinical experience and understanding about rhGH use in patients with pycnodysostosis and would be valuable in providing a step-by-step approach for similar cases to come [7]. The gene discussed is GH1; the disease is pycnodysostosis.